ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Study of the thrombin generation in anticoagulated patients with hemorrhage complications

R. A. Gauthier1, A. Desvoilhes2, L. Talon2, T. Sinegre2, J. Schmidt3, F. Moustafa3, D. Teissandier4, A. Lebreton5

1Hematology Department, CHU Clermont-Ferrand, 2Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, Auvergne, France, 3Emergency Unit, CHU Clermont Ferrand, Clermont-Ferrand, Auvergne, France, 4 CHU Clermont Ferrand, Clermont-Ferrand, Auvergne, France, 5Service d’hématologie biologique, CHU Clermont-Ferrand, Clermont-Ferrand, France, Clermont-Ferrand, Rhone-Alpes, France

Abstract Number: PB0450

Meeting: ISTH 2022 Congress

Theme: Venous Thromboembolism » VTE Treatment

Background: While prothrombin complex concentrates (PCC) have been proven to be effective to reverse vitamin K antagonists (VKA), PCC is also used to reverse direct oral anticoagulants (DOACs) in a non-specific manner. We previously measured thrombin generation (TG) following the reversion of bleeding patients treated with OAC with CAT method and showed a hypercoagulable state after reversion for patients treated with DOACs (ISTH 2019 Poster PB1659).

Aims: Our study, supported by Stago, aims to evaluate the new thrombin generation system (ST-Genesia®) using leftover plasma of our study.

Methods: Plasma of patients treated with either VKA, rivaroxaban(R) or apixaban(A) were collected at the patients’ arrival (V1), 30mins(V2), 6H(V3) and 24H(V4) post-reversion. We compared with Bland-Altman plots peaks and endogenous thrombin potentials (ETP) obtained with both instruments.

Results: Hypercoagulability was detected for DOACs at V2 (mean ± SD ETP A: 2302±693.3; R: 2628±1111 nM.min) (ETP healthy controls intervals: 1017 to 1667 nM.min as 5th and 95th percentiles) and was maintained to V4 (mean ± SD ETP A: 2348±321,2; R: 2495±418,5 nM.min). No hypercoagulability was detected for VKAs after reversion (mean ± SD ETP V2: 982.0±480.5; V3: 1137±326.8; V4: 1061±365.6 nM.min). As for the peak (healthy controls intervals: 178,2 to 359,6 nM as 5th and 95th percentiles), only patients treated with rivaroxaban became hypercoagulable at V4 (mean ± SD R: 427.7± 38.78 nM).

Conclusion(s): Patients treated with VKA and reversed with PCC have regained a normal coagulation, while patients treated with DOACs and reversed with PCC had hypercoagulability, as observed with CAT. Agreements between the two methods were satisfactory for both TG parameters.

Image 1

ETP and peak measured in orally anticoagulated patients in hemorrhage following the reversion by PCC obtained with ST-Genesia® using STG-ThromboScreen TM-. Reference intervals of ETP and peak are represented in beige. Reference intervals are expressed as mean and 5th-95th percentiles.

To cite this abstract in AMA style:

Gauthier RA, Desvoilhes A, Talon L, Sinegre T, Schmidt J, Moustafa F, Teissandier D, Lebreton A. Study of the thrombin generation in anticoagulated patients with hemorrhage complications [abstract]. https://abstracts.isth.org/abstract/study-of-the-thrombin-generation-in-anticoagulated-patients-with-hemorrhage-complications/. Accessed September 27, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/study-of-the-thrombin-generation-in-anticoagulated-patients-with-hemorrhage-complications/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley